Shift from Darbepoetin-α to Continuous Erythropoietin Receptor Activator Decreases Serum Aluminium Concentration in Patients on Hemodialysis
Conclusion We found the shift from DPO to CERA results in lower Al levels, a reduced inflammatory response, and an increase in RBC number and PTH level in uremic patients on hemodialysis.
Source: Environmental Toxicology and Pharmacology - Category: Environmental Health Source Type: research
More News: Bleeding | Calcium | Cholesterol | Dialysis | Drugs & Pharmacology | Environmental Health | Hemodialysis | Hormones | Men | Toxicology